Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 3/20 | 0.45 |
| ▸ | CCNC | P24863 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | IDH2 | P48735 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10095686 | 0.87 | GSK3A (0.47) | GSK3AGSK3BKDRMAPK14TNNI3K | |
| SCHEMBL13152069 | 0.85 | ITGB3 (0.47) | MEN1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL10097283 | 0.84 | TSHR (0.47) | KDRBRAFMEN1KMT2AHTT | |
| SCHEMBL13152115 | 0.83 | GRIK2 (0.46) | MEN1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL13152063 | 0.83 | MTNR1B (0.51) | MEN1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL13152096 | 0.81 | KMT2A (0.46) | MEN1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL13152066 | 0.81 | GRIK2 (0.45) | MEN1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL10097617 | 0.79 | TP53 (0.47) | KDRMEN1KMT2AHTTLMNA | |
| SCHEMBL10252373 | 0.79 | MTNR1B (0.48) | KDRMEN1KMT2AHTTLMNA | |
| SCHEMBL13152067 | 0.78 | GRIK2 (0.42) | MEN1KMT2AHTTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | GSK3A 1223/4885GSK3B 1270/4885KDR 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.